DIA_CENTRAL:T2D Treatment Pattern in Central Europe

10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only patients with non-missing results are reported.

10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only patients with non-missing results are reported.

10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only patients with non-missing results are reported.

Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of gender are: * Female * Male

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of gender are: * Female * Male

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of gender are: * Female * Male

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of race are: * Black * Non-black

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of race are: * Black * Non-black

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of race are: * Black * Non-black

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Clinical parameter relevant for Type 2 Diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of percentage (%) of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of percentage of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of percentage of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only patients with non-missing values are reported.

Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only participants with non-missing results are reported.

Clinical parameter relevant for Type 2 Diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician. Only participants with non-missing results are reported.

Number of patients in each category of prescription of a respective modern Type 2 Diabetes (T2D) medication according to prescribing specialist is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant cardiovascular disease (CVD) and/or chronic kidney disease (CKD) medication at study index date 1 according to prescribing specialist is reported. The reported concomitant CVD and/or chronic CKD medications are: * Antihypertensive angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) * Statins * Low dose aspirin * Beta blockers * Diuretics * Others

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant T2D medications at study index date 1 according to prescribing specialist is reported. The concomitant T2D medications reported are: * Metformin * Sulfonylurea * Acarbose * Pioglitazone * Insulin * Others

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients for each type of physician specialties involved in decision for T2D therapy discontinuation according to prescribing specialist is reported.

Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

Population: Patients in the full analysis set (FAS) who discontinued the study medication. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.

Number of patients in each category of congestive heart failure (CHF) confirmed by echocardiography according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients in the Prescribed patient set (PPS) (all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician) with congestive heart failure.

Number of patients in each category of different types of cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The following types of cardiovascular diseases are reported: * Myocardial infarction * Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)) * Ischemic heart disease * Congestive heart failure * Stroke * Peripheral arterial disease The categories reported for each type of cardiovascular disease are: * Yes * No * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of employment status are: * Employed * Not employed * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of employment status are: * Employed * Not employed * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients in each category of employment status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of employment status are: * Employed * Not employed * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients in each category of employment status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of employment status are: * Employed * Not employed * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients in each category of family status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients in each category of family status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of family status are: * Single * Married * Divorced * Widowed * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician..

Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients in each category of insurance status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of insurance status are: * Not insured * Statutory insured * Privately insured * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other

Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

Population: Patients in the full analysis set (FAS) who discontinued the study medication and who were initiated on type 2 diabetes (T2D) medication by endocrinologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.

Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other

Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

Population: Patients in the full analysis set (FAS) who discontinued the study medication and who were initiated on type 2 diabetes (T2D) medication by cardiologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.

Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other

Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

Population: Patients in the full analysis set (FAS) who discontinued the study medication and who were initiated on type 2 diabetes (T2D) medication by diabetologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.

Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other

Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

Population: Patients in the full analysis set (FAS) who discontinued the study medication. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.

Number of patients in each category of reason for discontinuation of type 2 diabetes (T2D) medication by country is reported. The categories of reason for discontinuation of T2D medication are: * Lack of efficacy * Medication administration * Financial burden regarding co-payment * Lost to follow-up * Adverse event * Other

Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

Population: Patients in the full analysis set (FAS) who discontinued the study medication. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.

Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The categories of status of T2D medication are: * Discontinued * Continued

Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

Population: Patients of the full analysis set (FAS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.

Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The categories of status of T2D medication are: * Discontinued * Continued

Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

Population: Patients of the full analysis set (FAS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.

Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The categories of status of T2D medication are: * Discontinued * Continued

Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

Population: Patients of the full analysis set (FAS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. FAS included all patients from the prescribed patient set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.

Number of patients in each category of status of type 2 diabetes (T2D) medication at index date 2 according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. The categories of status of T2D medication are: * Discontinued * Continued

Time frame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).

Population: Full Analysis set (FAS): All patients from Prescribed patient Set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.

Number of patients in each category of the different types of cardiovascular disease is reported. The following types of cardiovascular diseases are reported: * Myocardial infarction * Cardiology intervention (Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Grafting (CABG)) * Ischemic heart disease * Congestive heart failure * Stroke * Peripheral arterial disease The categories reported for each type of cardiovascular disease are: * Yes * No * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients in each category of the different types of congestive heart failure (CHF) which was confirmed by echocardiography is reported. The reported categories of congestive heart failure confirmed by echocardiography are: * Yes * No * Unknown

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients in the Prescribed patient set (PPS) (all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician) with congestive heart failure.

Number of patients with cardiovascular disease (CVD) is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients with any type of cardiovascular disease (CVD) or without CVD according to prescribing specialist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) and without CKD by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients in the prescribed patient set (PPS) with available eGFR and UACR status. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients with chronic kidney (CKD) (patients for whom CKD was reported as a comorbidity) or without CKD by physician's assessment according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients with chronic kidney (CKD) and without CKD by physician's assessment according to prescribing specialist is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients with chronic kidney disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status - according to prescribing specialist is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients in the Prescribed patient set (PPS) (all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician) with documentation of eGFR and/or UACR status are reported.

Number of patients with Chronic Kidney Disease (CKD) by estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) status is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients in the Prescribed patient set (PPS) (all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician) with documentation of of eGFR / UACR status.

Number of patients with chronic kidney disease (CKD) by physician's assessment (patients for whom CKD was reported as a comorbidity) is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients with documentation of estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) status is reported.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by cardiologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by diabetologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Patients of the prescribed patient set (PPS) who were initiated on type 2 diabetes (T2D) medication by endocrinologist. PPS included all patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective T2D medication and whose documentation was electronically signed by the physician.

Number of patients with or without at least one cardiovascular disease (CVD) type according to type 2 diabetes (T2D) medication initiated at study index date 1 is reported. Patients with cardiovascular disease were considered patients for whom 'History of acute myocardial infarction', 'History of cardiology intervention', 'Ischemic heart disease', 'Congestive heart failure', 'History of stroke' or 'Peripheral arterial disease', were documented as comorbidities.

Time frame: At study index date 1 (i.e. between September 2018 and December 2018).

Population: Prescribed patient set (PPS): All patients fulfilling inclusion and exclusion criteria who have received a first prescription of a respective type 2 diabetes (T2D) medication and whose documentation was electronically signed by the physician.

Time to discontinuation of type 2 diabetes (T2D) treatment according to study medication is reported. Time to discontinuation of T2D medication was estimated by Kaplan-Meier analysis. Patients who did not discontinue study medication at study index date 2 were censored.

Time frame: From date of first prescription (study index date 1) to stop date of initial type 2 diabetes (T2D)) medication (documented at index date 2), up to 14 months..

Population: Full Analysis set (FAS): All patients from prescribed patient Set (PPS) with documentation at index date 2 and whose documentation was electronically signed by the physician. Patients included before the protocol amendment needed an additional signed informed consent at index date 2.